This study is available free. Just click on this link to download it. As a way of background, this is the second Phase 3 study for ISTURISA (osilodrostat). The first phase 3 study, LINC 3,
News from pharmaceutical companies and other related healthcare organizations
A conversation with Amryt’s new president for the Americas, Sheila Frame
We caught up with Sheila a few weeks ago at the Acromegaly Community Conference near San Francisco. We had a captivating chat about Mycapssa (oral octreotide) and about Amryt’s start in Dublin, Ireland, just six years ago, its philosophy, brand, and plans.
Good news from Amryt for acromegaly patients in Europe
Amryt Pharma announced positive results for the MPOWERED phase 3 trial for Mycapssa® oral octreotide for acromegaly patients, in a recent press release. The trial paves the way for the approval of Mycapssa® by the EMA.
Corcept’s Grace Study for a new Cushing’s drug; an update
The Corcept Therapeutics “Grace Study”, designed to evaluate the benefits and side effects of a new medication for people with endogenous Cushing’s syndrome, continues full steam ahead. The company recently announced the availability of new
Emotional wellness with acromegaly
Kudos to Pfizer’s new series on patient support. The first one features critical advice on emotional and mental help support! The materials provide valuable content given the importance of mental health issues to acromegaly patients.
Big news for acromegaly at Crinetics
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Two clinical trials for acromegaly patients: see if you are eligible.
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers
The Road to MYCAPSSA: A Conversation with Dr. Bill Ludlam
With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed 58% of patients maintained normal IGF-1 levels with the new oral
Crinetics new drug candidate for acromegaly Paltusotine awarded Orphan Drug Designation
From a Crinetics Pharmaceutical press release: Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced that the
More information on Recordati’s new Cushing’s drug Isturisa
In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and Endocrinology. “The exciting data, published today, underscore the efficacy and safety
More news on Isturisa for Cushing’s
In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States, announced the full availability of Isturisa® for the treatment of adult
From Endocrine Web: New Oral Acromegaly Treatment Has No Needles Required
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,